MOUNJARO

Mounjaro is the first GIP and GLP-1 receptor agonist, which works on the glucose-dependent insulinotropic polypeptide (GIP) receptors and the glucagon-like peptide-1 (GLP-1) receptors.

Mounjaro works to lower blood sugar by helping the pancreas make more insulin, lowering the amount of sugar your liver makes, and slowing the rate food passes through your body, making you feel full longer. It does this by activating the two receptors, GIP and GLP-1, which are natural incretin hormones that help regulate blood sugar levels.

Mounjaro injection became an FDA-approved medicine on May 13, 2022, to improve blood sugar (glucose) levels in adults with type 2 diabetes mellitus when used together with diet and exercise. Mounjaro is not for use in people with type 1 diabetes. It is not known if this medicine can be used in people who have had pancreatitis.